Everest Medicines Limited has announced a connected transaction involving a lease agreement. On January 26, 2026, Everest Medicines Trading (Shanghai) Co., Ltd., a wholly-owned subsidiary of Everest Medicines, entered into a lease agreement with Kang Pu as the lessor. The transaction pertains to the leasing of certain premises for a specified term. Mr. Wei Fu, a non-executive director with a material interest in the agreement, abstained from voting on the relevant board resolutions. The company confirmed that all necessary approval requirements under the Hong Kong Listing Rules have been observed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260126-12001551), on January 26, 2026, and is solely responsible for the information contained therein.